Zdrowie i gospodarka · 30.03.2004
International Conference on Harmonisation; Draft Guidance on E2E Pharmacovigilance Planning; Availability
The Food and Drug Administration (FDA) is announcing the availability of a draft guidance entitled "E2E Pharmacovigilance Planning." The draft guidance was prepared under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The draft guidance describes a method for summarizing the identified risks of a drug, the potential for important unidentified risks, and the potentially at-risk populations and situations that were not studied before the drug was approved. The draft guidance is intended to foster better and earlier planning of pharmacovigilance activities, especially in preparation for the early postmarketing period of a new drug.